1. Home
  2. LCFY vs PMCB Comparison

LCFY vs PMCB Comparison

Compare LCFY & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LCFY
  • PMCB
  • Stock Information
  • Founded
  • LCFY 2009
  • PMCB 1996
  • Country
  • LCFY Australia
  • PMCB United States
  • Employees
  • LCFY N/A
  • PMCB N/A
  • Industry
  • LCFY
  • PMCB Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LCFY
  • PMCB Health Care
  • Exchange
  • LCFY Nasdaq
  • PMCB Nasdaq
  • Market Cap
  • LCFY 5.9M
  • PMCB 5.8M
  • IPO Year
  • LCFY 2022
  • PMCB N/A
  • Fundamental
  • Price
  • LCFY $4.41
  • PMCB $0.90
  • Analyst Decision
  • LCFY
  • PMCB
  • Analyst Count
  • LCFY 0
  • PMCB 0
  • Target Price
  • LCFY N/A
  • PMCB N/A
  • AVG Volume (30 Days)
  • LCFY 472.2K
  • PMCB 38.8K
  • Earning Date
  • LCFY 08-26-2025
  • PMCB 08-11-2025
  • Dividend Yield
  • LCFY N/A
  • PMCB N/A
  • EPS Growth
  • LCFY N/A
  • PMCB N/A
  • EPS
  • LCFY N/A
  • PMCB 3.19
  • Revenue
  • LCFY $2,668,385.00
  • PMCB N/A
  • Revenue This Year
  • LCFY N/A
  • PMCB N/A
  • Revenue Next Year
  • LCFY N/A
  • PMCB N/A
  • P/E Ratio
  • LCFY N/A
  • PMCB $0.28
  • Revenue Growth
  • LCFY N/A
  • PMCB N/A
  • 52 Week Low
  • LCFY $2.51
  • PMCB $0.80
  • 52 Week High
  • LCFY $13.98
  • PMCB $2.42
  • Technical
  • Relative Strength Index (RSI)
  • LCFY 43.17
  • PMCB 41.85
  • Support Level
  • LCFY $4.30
  • PMCB $0.84
  • Resistance Level
  • LCFY $4.74
  • PMCB $0.95
  • Average True Range (ATR)
  • LCFY 0.43
  • PMCB 0.07
  • MACD
  • LCFY -0.14
  • PMCB -0.00
  • Stochastic Oscillator
  • LCFY 4.14
  • PMCB 39.96

About LCFY Locafy Limited

Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has two operating segments: Publishing and SEO agency. Under the Publishing segment are products and services that the Company offers that are related to digital properties (i.e. mastheads) that it owns e.g. business data published on Hotfrog, advertising placed on AussieWeb, articles published on scoop.com.au. In contrast, under the SEO Agency segment are products and services that are applied to digital properties that are owned and operated by third parties. It derives a majority of its revenue in North America from SEO Agency.

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Share on Social Networks: